Pasithea Wins FDA Clearance for Phase 2 Trial of PAS-004 in Cutaneous Neurofibromas

• Pasithea Therapeutics received FDA clearance to begin a randomized, placebo-controlled Phase 2 trial of PAS-004 for NF1-associated cutaneous neurofibromas.
• The condition affects over 95% of people with NF1 and has no FDA-approved systemic therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611030700PRIMZONEFULLFEED9868670) on November 03, 2026, and is solely responsible for the information contained therein.